Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

UCLA Researchers in collaboration with DPAG researchers from the Paterson and Herring Groups have identified a biomarker for increased risk of early mortality in patients with heart failure. Associate Professor Neil Herring is senior author.

A UCLA-led study in collaboration with Harvard and Oxford University researchers has revealed a new way to predict which patients with "stable" heart failure - those who have heart injury but do not require hospitalisation - have a higher risk of dying within one to three years.

Although people with stable heart failure have similar characteristics, some have rapid disease progression while others remain stable. The research shows that patients who have higher levels of neuropeptide Y, a molecule released by the nervous system, are 10 times more likely to die within one to three years than those with lower levels of neuropeptides.

The UCLA-led paper, published in JAMA Cardiology, is in collaboration with DPAG researchers, with Associate Professor Neil Herring as senior author.

The study was funded by grants from the National Institutes of Health and the British Heart Foundation.

More information can be found on the UCLA website.

The full paper "Coronary Sinus Neuropeptide Y Levels and Adverse Outcomes in Patients With Stable Chronic Heart Failure" is available to read in JAMA Cardiology.

UCLA study Dec 2019

Similar stories

REF 2021 results

DPAG researchers showcased at premier European Society of Cardiology meeting

DPAG scientists across four research groups were highlighted at the major annual European Society of Cardiology basic science conference (FCVB 2022). Congratulations are in order for Dr KC Park on receiving the Young Investigator Award and to Dr Elisabetta Gamen on winning the Moderated Poster Prize.

Oxford Parkinson’s Disease Centre awarded £3.8 million to reveal the role of calcium in Parkinson’s

A collaborative research team led by the Oxford Parkinson’s Disease Centre (OPDC) has been awarded a £3.8 million Wellcome Trust Collaborative Award to study the function of calcium in dopamine neurons, and how this is plays a role in Parkinson’s. Their research will help explain how and why dopamine neurons are vulnerable in the disease and look at how they may be preserved.

The effect of nuclear pH on cardiac gene expression

Research led by Dr Alzbeta Hulikova and Professor Pawel Swietach has, for the first time, described the potential regulation of nuclear acid-base chemistry in neonatal and adult cardiomyocytes, and explained its relevance in the context of heart physiology and pathology.

A role of sleep in tinnitus identified for the first time

Phantom percepts, such as subjective tinnitus, are driven by fundamental changes in spontaneous brain activity. Sleep is a natural example of major shifts in spontaneous brain activity and perceptual state, suggesting an interaction between sleep and tinnitus that has so far been little considered. In a new collaborative review article from DPAG’s auditory and sleep neuroscientists, tinnitus and sleep research is brought together for the first time, and, in conclusion, they propose a fundamental relationship between natural brain dynamics and the expression and pathogenesis of tinnitus.